| Liver stiffness plus platelet count can be used to exclude high‐risk oesophageal varices NS Ding, T Nguyen, DM Iser, T Hong, E Flanagan, A Wong, L Luiz, ... Liver International 36 (2), 240-245, 2016 | 103 | 2016 |
| Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis C Qu, D Zheng, S Li, Y Liu, A Lidofsky, JA Holmes, J Chen, L He, L Wei, ... Hepatology 68 (3), 1125-1139, 2018 | 94 | 2018 |
| Interferon-free combination therapies for the treatment of hepatitis C: current insights JA Holmes, AJ Thompson Hepatic medicine: evidence and research, 51-70, 2015 | 78 | 2015 |
| Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection ML Yeh, CF Huang, CI Huang, JA Holmes, MH Hsieh, YS Tsai, PC Liang, ... Journal of hepatology 73 (1), 62-71, 2020 | 70 | 2020 |
| IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon‐α JA Holmes, T Nguyen, D Ratnam, NM Heerasing, JV Tehan, ... Journal of gastroenterology and hepatology 28 (5), 861-866, 2013 | 66 | 2013 |
| Direct-acting antiviral treatment for hepatitis C JA Holmes, SM Rutledge, RT Chung The Lancet 393 (10179), 1392-1394, 2019 | 64 | 2019 |
| Cluster of 4 cases of esophageal squamous cell cancer developing in adults with surgically corrected esophageal atresia—time for screening to start CS Jayasekera, PV Desmond, JA Holmes, M Kitson, ACF Taylor Journal of Pediatric Surgery 47 (4), 646-651, 2012 | 59 | 2012 |
| Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis AJ Kruger, BC Fuchs, R Masia, JA Holmes, S Salloum, M Sojoodi, ... Hepatology Communications 2 (5), 529-545, 2018 | 57 | 2018 |
| Hepatitis B reactivation during or after direct acting antiviral therapy–implication for susceptible individuals JA Holmes, ML Yu, RT Chung Expert opinion on drug safety 16 (6), 651-672, 2017 | 56 | 2017 |
| Macrophage activation marker soluble CD163 is a dynamic marker of liver fibrogenesis in human immunodeficiency virus/hepatitis C virus coinfection A Lidofsky, JA Holmes, ER Feeney, AJ Kruger, S Salloum, H Zheng, ... The Journal of infectious diseases 218 (9), 1394-1403, 2018 | 53 | 2018 |
| A long noncoding RNA regulates hepatitis C virus infection through interferon alpha–inducible protein 6 X Liu, X Duan, JA Holmes, W Li, SH Lee, Z Tu, C Zhu, S Salloum, ... Hepatology 69 (3), 1004-1019, 2019 | 46 | 2019 |
| MicroRNA 130a regulates both hepatitis C virus and hepatitis B virus replication through a central metabolic pathway X Duan, S Li, JA Holmes, Z Tu, Y Li, D Cai, X Liu, W Li, C Yang, B Jiao, ... Journal of virology 92 (7), 10.1128/jvi. 02009-17, 2018 | 44 | 2018 |
| Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and … S Salloum, JA Holmes, R Jindal, SS Bale, C Brisac, N Alatrakchi, ... Hepatology 64 (6), 1951-1968, 2016 | 44 | 2016 |
| Fatty acids activate the transcriptional coactivator YAP1 to promote liver fibrosis via p38 mitogen-activated protein kinase S Salloum, AJ Jeyarajan, AJ Kruger, JA Holmes, T Shao, M Sojoodi, ... Cellular and Molecular Gastroenterology and Hepatology 12 (4), 1297-1310, 2021 | 40 | 2021 |
| Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience GC Lovett, T Nguyen, DM Iser, JA Holmes, R Chen, B Demediuk, G Shaw, ... World journal of hepatology 9 (1), 48, 2017 | 36 | 2017 |
| ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response JA Holmes, SK Roberts, RJ Ali, GJ Dore, W Sievert, GW McCaughan, ... Hepatology 59 (6), 2152-2160, 2014 | 32 | 2014 |
| Hepatitis C: an update J Holmes, A Thompson, S Bell Australian Journal of General Practice 42 (7), 452, 2013 | 29 | 2013 |
| Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C virus infection treated with oral, interferon-free, direct-acting antiviral therapy ME Sise, J Wisocky, IA Rosales, D Chute, JA Holmes, KM Corapi, ... Kidney international reports 1 (3), 135-143, 2016 | 28 | 2016 |
| Australian consensus recommendations for the management of hepatitis B JS Lubel, SI Strasser, AJ Thompson, BC Cowie, J MacLachlan, NL Allard, ... Medical Journal of Australia 216 (9), 478-486, 2022 | 27 | 2022 |
| Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID‐19 pandemic R Shah, E Wright, G Tambakis, J Holmes, A Thompson, W Connell, ... Internal Medicine Journal 51 (7), 1038-1042, 2021 | 27 | 2021 |
